Oxford Biomedica plc (FRA:OXOA)
Germany · Delayed Price · Currency is EUR 9.45
-0.25 (-2.58%)
At close: Jan 30, 2026
Oxford Biomedica Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 151.21 | 128.8 | 89.54 | 139.99 | 142.8 | 87.73 | |
Revenue Growth (YoY) | 55.44% | 43.84% | -36.04% | -1.97% | 62.77% | 36.95% |
Cost of Revenue | 84.49 | 75.78 | 49.81 | 70.81 | 60.16 | 41.66 |
Gross Profit | 66.72 | 53.02 | 39.73 | 69.18 | 82.64 | 46.07 |
Selling, General & Admin | 94.22 | 91.54 | 116.97 | 23.12 | 13.95 | 11.26 |
Research & Development | 4.28 | 4.54 | 11.47 | 94.82 | 47.42 | 40.47 |
Other Operating Expenses | -4.34 | -5.25 | -2.8 | -2.31 | -0.87 | -0.8 |
Operating Expenses | 94.16 | 90.83 | 125.64 | 115.64 | 60.51 | 50.94 |
Operating Income | -27.44 | -37.81 | -85.91 | -46.46 | 22.13 | -4.86 |
Interest Expense | -12.02 | -9.84 | -10.67 | -8.69 | -0.86 | -0.87 |
Interest & Investment Income | 2.55 | 3.24 | 4.91 | 0.97 | - | 0.03 |
Currency Exchange Gain (Loss) | 3.09 | -0.62 | 1.94 | -7.98 | - | - |
Other Non Operating Income (Expenses) | -0.47 | -0.67 | -0.53 | -0.07 | -0.03 | -0.04 |
EBT Excluding Unusual Items | -34.29 | -45.7 | -90.26 | -62.21 | 21.25 | -5.74 |
Merger & Restructuring Charges | -1.5 | -1.5 | - | -5.1 | -1.2 | - |
Gain (Loss) on Sale of Assets | -0.07 | -0.07 | 1.02 | 21.39 | - | - |
Asset Writedown | - | - | -99.28 | -0.05 | -0.17 | -0.83 |
Pretax Income | -37.56 | -47.27 | -188.53 | -45.98 | 19.88 | -6.57 |
Income Tax Expense | 1.53 | 1.34 | -4.37 | -0.82 | 0.87 | -0.33 |
Earnings From Continuing Operations | -39.09 | -48.61 | -184.16 | -45.16 | 19.01 | -6.25 |
Minority Interest in Earnings | 2.02 | 5.42 | 26.67 | 6 | - | - |
Net Income | -37.07 | -43.19 | -157.49 | -39.16 | 19.01 | -6.25 |
Net Income to Common | -37.07 | -43.19 | -157.49 | -39.16 | 19.01 | -6.25 |
Shares Outstanding (Basic) | 104 | 103 | 97 | 95 | 83 | 80 |
Shares Outstanding (Diluted) | 104 | 103 | 97 | 95 | 86 | 80 |
Shares Change (YoY) | 2.96% | 7.15% | 1.82% | 10.76% | 7.10% | 9.95% |
EPS (Basic) | -0.36 | -0.42 | -1.63 | -0.41 | 0.23 | -0.08 |
EPS (Diluted) | -0.36 | -0.42 | -1.63 | -0.41 | 0.22 | -0.08 |
Free Cash Flow | -12.03 | -58.16 | -38.35 | -28.91 | 15.99 | -10.24 |
Free Cash Flow Per Share | -0.12 | -0.56 | -0.40 | -0.30 | 0.19 | -0.13 |
Gross Margin | 44.13% | 41.17% | 44.37% | 49.42% | 57.87% | 52.52% |
Operating Margin | -18.15% | -29.35% | -95.95% | -33.19% | 15.50% | -5.54% |
Profit Margin | -24.51% | -33.53% | -175.89% | -27.97% | 13.31% | -7.12% |
Free Cash Flow Margin | -7.95% | -45.16% | -42.83% | -20.65% | 11.20% | -11.68% |
EBITDA | -12.57 | -20.89 | -70.01 | -31.1 | 32.66 | 3.6 |
EBITDA Margin | -8.31% | -16.22% | -78.19% | -22.22% | 22.87% | 4.10% |
D&A For EBITDA | 14.88 | 16.92 | 15.9 | 15.36 | 10.53 | 8.46 |
EBIT | -27.44 | -37.81 | -85.91 | -46.46 | 22.13 | -4.86 |
EBIT Margin | -18.15% | -29.35% | -95.95% | -33.19% | 15.50% | -5.54% |
Effective Tax Rate | - | - | - | - | 4.37% | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.